Posted by Michael Wonder on 07 Dec 2023
Solid Biosciences receives FDA fast track designation for Duchenne muscular dystrophy gene therapy SGT-003
7 December 2023 - Next generation gene transfer therapy to treat Duchenne receives FDA fast track Designation.
Solid Biosciences today announced that it has received fast track designation from the US FDA for SGT-003, the company’s next generation Duchenne muscular dystrophy gene therapy candidate.
